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Previous examination of the accessibility of a panel of single-Cys mutants in transmembrane domain III (TMDIII) of the yeast mitochondrial
citrate transport protein to the hydrophilic, cysteine-specific methanethiosulfonate reagent MTSES enabled identification of the water-accessible
surface of this TMD. Further studies on the effect of citrate on MTS reagent accessibility, indicated eight sites within TMD III at which citrate
conferred temperature-independent protection, thus providing strong evidence for participation of these residues in the formation of a portion of
the substrate translocation pathway. Unexpectedly, citrate did not protect against inhibition of the Leu120Cys variant, despite its location on a
water- and citrate-accessible surface of the TMDIII helix. This led to the hypothesis that in the 3-dimensional CTP structure, TMDIV packs
against TMDIII in a manner such that the Leu120 side-chain folds behind the side-chain of Gln182. The present investigations addressed this
hypothesis by examining the properties of the Gln182Cys single mutant and the Leu120Cys/Gln182Ala double mutant. We observed that in
contrast to our findings with the Leu120Cys mutant, citrate did protect the Gln182Cys variant against MTSES-mediated inhibition. Importantly,
truncation of the Gln182 side-chain to Ala enabled citrate to protect the Leu120Cys double mutant against inhibition. In combination these data
support the idea that the Gln182 side-chain lines the transport path and sterically blocks access of citrate to the Leu120 side-chain. In a parallel
series of investigations, we constructed 24 single-Cys substitution mutants that were chosen based on their hypothesized importance in substrate
binding and/or translocation. We observed that substitution of Cys for residues E34, K37, K83, R87, Y148, D236, K239, T240, R276, and R279
resulted in ≥98% inactivation of CTP function, suggesting an essential structural and/or mechanistic role for these native residues. Superposition
of this functional data onto a detailed 3-dimensional homology model of the CTP structure indicates that the side-chains of each of these residues
project into the putative transport pathway. We hypothesize that a subset of these residues, in combination with four previously identified essential
residues, define the citrate binding site(s) within the CTP.
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The mitochondrial citrate transport protein (i.e., CTP) resides
within the inner mitochondrial membrane and in higher
eukaryotes catalyzes an obligatory exchange of the dibasic
form of a tricarboxylic acid (e.g., citrate, isocitrate, or cis-
aconitate) for either another tricarboxylate, a dicarboxylate, or
phosphoenolpyruvate [1]. The CTP plays a major role in
intermediary metabolism since following the efflux of citrate
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across the outer mitochondrial membrane through VDAC, the
resulting cytoplasmic citrate provides the prime carbon source
supplying the fatty acid, triacylglycerol, and cholesterol
biosynthetic pathways [2–5]. Furthermore, via the sequential
action of citrate lyase and malate dehydrogenase, cytoplasmic
citrate provides for the production of NAD+, a cofactor that is
required for continuation of glycolysis.
Due to the importance of the CTP, our laboratory has
extensively investigated its structure/function relationships in
order to understand the molecular mechanism underlying its
function [6–8]. In recent years, we have focused our experi-
mental efforts on the yeast mitochondrial CTP, since following
high-level expression, purification and functional reconstitution
in liposomes, the transporter displays a high specific transport
activity [9]. Accordingly we have: (i) constructed a Cys-less
form of the transporter which displays native functional
properties [10]; (ii) used Cys-scanning mutagenesis combined
with labeling the resulting single-Cys mutants with different
probes to identify the residues within TMDs III and IV that form
elements of the translocation pathway [11–13]; (iii) developed a
detailed 3-dimensional homology model of the CTP and
superimposed our functional data to delineate the translocation
pathway [14]; and (iv) shown that in detergent micelles both the
Cys-less and wild-type CTP exist as homodimers [15].
With this background in mind, the present investigations
sought to address the following two issues. First, we examined our
hypothesis that the reason for the unexpected inability of citrate to
protect against MTSES-mediated inhibition of the Leu120Cys
CTP variant [13], arises from steric blockage by the Gln182 side-
chain which we proposed packs against the Leu120 side-chain
and resides more proximal to the translocation pathway. Second,
we examined the effect of Cys substitution at 24 locations, which
were chosen based on their predicted importance in the CTP
mechanism. In combination, the data obtained from these studies
support our hypothesized Gln182–Leu120 steric interaction and
indicate an important subset of residues that are essential for CTP
function. Furthermore, superposition of this additional data onto
the 3-dimensional CTP homology model provides new insight
into the potential function of these essential residues in the CTP
structure-based mechanism.
2. Materials and methods
2.1. Construction, overexpression, and isolation of CTP mutants
Single-Cys CTP variants were prepared exactly as previously described
[12]. The Leu120Cys/Gln182Ala double mutant was prepared using the
Leu120Cys CTP sequence in pET-21a(+) as the starting template during PCR
amplification.
2.2. Incorporation of CTP mutants into phospholipid vesicles and
determination of their kinetic properties
Overexpressed, detergent-solubilized and partially purified Cys-less and
other CTP variants were reconstituted into liposomes via the freeze–thaw-
sonication technique as previously described [6,9]. The kinetic properties (Km
and Vmax) of the Cys-less, Gln182Cys, Leu120Cys, and Leu120Cys/Gln182Ala
doublemutant CTP variants were determined as previously detailed [13]. Briefly,immediately prior to the transport assay, a sample was thawed, sonicated on ice,
and extraliposomal citrate was removed by chromatography on a Dowex column
in a Pasteur pipette. Proteoliposomes (45 μl) were preincubated with 3.5 μl of
either buffer [6] (experimental sample) or 200 mM BTC (control sample) for
10 min and were then further incubated with 3.5 μl of deionized/distilled water
for an additional 10 min. The transport reaction was triggered via the addition of
21.5 μl of varying concentrations of [1,5-14C] citrate (Amersham Biosciences).
Typically, 10 different citrate concentrations ranging from 0.08 to 2 mM, which
bracket the Km value, were employed. Following transport incubations that
ranged from 12 s to 2.5 min (depending on the intrinsic activity of a given CTP
mutant), the experimental sample was quenched by the addition of 3.5 μl of
200 mM BTC. The control sample received an equal volume of buffer. All the
transport reactions were conducted at room temperature (21 °C). Intraliposomal
radiolabeled citrate was then separated from the external radiolabel via
chromatography on small Dowex columns in Pasteur pipettes. The eluted (i.e.
intraliposomal) radiolabel was quantified via liquid scintillation counting. The
BTC-sensitive transport rate was calculated by subtracting the control value from
the experimental value at each substrate concentration. For these studies, care
was taken to ensure that initial rates were being measured. The rate of uptake
versus substrate concentration curves were fitted to the Michaelis–Menten
equation: v=Vmax×S/(Km+S) using a non-linear least squares curve fit.
The measurement of the specific citrate transport activity of the Cys-less and
other single-Cys CTP variants (i.e., Fig. 3) was similar to that described above.
The only notable differences are that proteoliposomes were preincubated with
3.5 μl of either buffer (experimental sample) or 200 mM BTC (control sample)
for 30 s and were then further incubated with 3.5 μl of deionized/distilled water
for an additional 30 s. The transport reactions were then triggered via the addition
of 21.5 μl of 3.58 mM [1,5-14C] citrate (citrate concentration in reaction mix is
1.0 mM, the specific radioactivity of the stock is approximately 2—3×104 cpm/
nmol). Transport reaction times ranged from 12 s to 50 min.
2.3. Determination of the extent of substrate protection against
MTSES-mediated inhibition of citrate transport
The assay for substrate protection against MTSES-mediated inhibition of
citrate transport was carried out as follows. Proteoliposomes (125 μl) were
incubated with water (10 μl) versus water (7 μl) plus MTSES (3 μl) versus
varying concentrations of unlabeled citrate (7 μl) plus MTSES (3 μl) for a period
of time (i.e., 30 s to 2 min) at room temperature (i.e., 21 °C). The concentration
of MTSES and the length of the incubation interval were determined by an initial
series of experiments with each CTP variant. When present, citrate was added
immediately prior to MTSES. Following incubation with MTSES with or
without citrate, the reactions were stopped via the addition of 6 ml of ice-cold
buffer (120 mM HEPES, 50 mM NaCl, 1 mM EDTA, pH 7.4). Unreacted
MTSES and citrate were removed by ultracentrifugation at approximately
412,000×g for 25 min at 6 °C. The proteoliposomal pellets were washed with 6
ml of ice-cold buffer and subsequently resuspended gently in 115 μl of buffer.
Transport reactions were conducted in duplicate with each resuspended pellet as
previously described [13]. For the cases where unlabeled citrate protected
against MTSES-mediated inhibition of CTP function, the percentage of control
activity versus citrate concentration curves were fitted to a modified one-site
binding equation: Y=A+[(B×S)/(EC50+S)], where S is the citrate concentra-
tion, Y is the percentage of control activity remaining in the presence of MTSES
plus a given citrate concentration S, A is the percent activity remaining when
only MTSES was present, and B is the maximal percent control activity obtained
via substrate protection. EC50 is the effective concentration of citrate that yields
one half-maximal protection against MTSES-mediated transport inhibition.
3. Results
3.1. Kinetic characterization of the Cys-less, L120C, Q182C,
and L120C/Q182A CTP variants
In order to address the issue of whether the side-chain of
TMD IVresidue Q182 sterically blocks the approach of citrate to
the side-chain of TMD III residue L120, we conducted a detailed
Fig. 1. Quantitative evaluation of the extent of substrate protection against
MTSES-mediated inhibition of CTP function with mutations at residues
Leu120 and/or Gln182. Proteoliposomes reconstituted with a given CTP
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well as the L120C/Q182A double mutant. As depicted in Table
1, the three Cys substitutionmutants displayedmodest decreases
in their apparent Km values. The Km of the Q182C variant
displays a clear statistically significant decrease, whereas the
decreased Km of the L120C and the L120C/Q182A variants
were of borderline statistical significance. The Vmax values of the
three mutants ranged from 3 to 19% of the Cys-less value. While
the reduced Km values partially compensated for the sharply
reduced Vmax values, the resulting catalytic efficiencies (i.e.,
Vmax/Km) were decreased to 7–32% of the control Cys-less
value.
3.2. Substrate protection against inhibition of each CTP
variant by MTSES
In previous studies [11,12] we had demonstrated that
MTSES effectively inhibits the L120C and the Q182C single
mutants. In the present investigation effective inhibition was
observed with the L120C/Q182A double mutant. For example,
a 2 min incubation with 10 mMMTSES yielded 86% inhibition
of CTP function. We then examined the ability of citrate to
protect against the MTSES-mediated inhibition of each of these
CTP variants. For these studies, in order to optimize the
possibility of observing substrate protection, we chose MTSES
concentrations and incubation times that yielded partial (i.e.,
45–85%) inhibition and tested the ability of various concentra-
tions of citrate to protect against inhibition of CTP function. As
depicted in Fig. 1, and consistent with our previous observations
[13], citrate offered no significant protection of the L120C
mutant. In contrast, citrate afforded a high level of protection
against the MTSES-mediated inhibition of the Q182C mutant,
with an EC50 value of 1.40 mM. This is consistent with our
prediction that Q182 is more proximal to the transport pathway
than is Leu120, and in fact directly lines the pore. Importantly,
with the double mutant in which we have truncated the side-
chain at position 182 (thereby removing the proposed steric
block at this position) the Cys at position 120 is highly
accessible to citrate such that this substrate affords excellent
protection against MTSES modification. An EC50 value of
0.90 mM was observed. This value is reasonably close to theTable 1
Kinetic characterization of cysless, L120C, Q182C, L120C/Q182ACTP variants
Km (mM) Vmax
(nmol/min/mg)
Vmax/Km
(nmol/min/mg/mM)
Cysless 0.479±0.071 2369±83 4946 (100%)
Leu120Cys 0.290±0.014a 456±26b 1572 (31.8%)
Gln182Cys 0.162±0.011b 60±4b 370 (7.5%)
Leu120Cys/
Gln182Ala
0.296±0.010a 103±8b 348 (7.0%)
Transport reactions and calculation of Km and Vmax were conducted as described
under Materials and methods. Data represent means±S.E. from at least four Vi
versus [S] profiles employing ten different citrate concentrations that bracketed
the Km value.
a Values are p<0.075.
b Values are p<0.01 from a two-tailed student's t test between the Cysless
CTP and individual CTP mutants.
variant were incubated with MTSES with or without varying concentrations of
unlabeled citrate at 21 °C. Following dilution and removal of extraliposomal
citrate plus unreacted MTSES, transport incubations were conducted and
analyzed as described under Materials and methods. The specific activity
values for the MTSES-inhibited Leu120Cys, Gln182Cys, and Leu120Cys/
Gln182Ala mutants, in the absence of external citrate, were 198.5, 5.3, and
22.0 nmol/min/mg protein, respectively. Data depict means from at least eight
incubations±S.E.Km value for this double mutant suggesting a possible
involvement of cysteine at position 120 in substrate binding
under these conditions.
Fig. 2 depicts the substrate protection data in the context of
the CTP homology-modeled structure [14]. Panel A depicts the
Gln182 side-chain as lining the substrate translocation pathway
and thus located more proximal to the pathway than is the
Leu120 side-chain. Panel B depicts the Gln182 side-chain as
Fig. 2. Depiction of Gln182 and Leu120 substrate protection data in the context of the CTP homology-modeled structure. A view into the transport pathway from the
cytosolic surface of the bilayer is presented. Residues at positions 120 and 182 are depicted as a space-filling representation within the CTP homology-modeled
structure [14]. Panel A depicts the cys-less CTP containing Leu120 and Gln182; Panel B depicts the Leu120Cys CTP variant; Panel C denotes the Gln182Cys variant;
and Panel D depicts the Leu120Cys/Gln182Ala double mutant. The transport pathway is denoted by the *.
Fig. 3. Specific citrate transport activities of single-cysteine CTP variants.
Overexpressed, solubilized Cys-less and single-Cys CTP variants were
reconstituted into phospholipid vesicles. Transport incubations were per-
formed at room temperature and BTC-sensitive [14C]citrate/citrate exchange
was measured. Specific activity data represent the means of triplicate
incubations±S.E. The specific transport activity of the Cys-less CTP was
1375 nmol/min/mg protein and represents the 100% value. Other conditions
were as described under Materials and methods.
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thereby preventing access to it by citrate. Panel C indicates that
as expected when Gln182 is mutated to Cys, the Cys residue is
readily accessible to citrate. Finally, Panel D indicates that when
the Gln182 side-chain is truncated by mutation to Ala, the
Leu120Cysmutated side-chain is now accessible to the transport
path (denoted by *).
3.3. Transport activities of a panel of single-cys substitution
mutants hypothesized to participate in substrate binding and/or
translocation
Based on our modeling studies we constructed 24 single-
Cys substitution mutants that were chosen based on their
hypothesized importance in substrate binding and/or translo-
cation. These residues were localized throughout the
homology-modeled CTP structure. As depicted in Fig. 3, we
found that Cys substitution for E34 and K37 (TMDI), K83 and
R87 (TMDII), D140 and Y148 (M2), D236 and K239
(TMDV), T240, and Q243 (M3), and R276 and R279
(TMDVI) was highly disruptive of CTP function (i.e., ≥96%
inhibition of function). (Note: certain of the above residues are
quite close to the membrane/matrix loop interface and thus
assignment to a given domain cannot be made with certainty at
present). In contrast, substitution for selected residues in M1
(i.e., T38, R39, D44, K45, S47, and K48), TMDII (F76), M2(i.e., K141, Q142, S143) and TMDV (T228 and V229) was
reasonably well-tolerated.
Fig. 4 depicts the superposition of the specific activity data of
those mutants that were most disruptive of CTP function (i.e.,
defined as causing ≥ 98% inactivation of CTP function) onto
Fig. 4. Depiction of essential residues within the 3-dimensional CTP homology
modeled structure. A view into the transport pathway from the cytosolic surface
of the bilayer is presented. Residues that display less than 2% of the starting Cys-
less CTP function are depicted as ball and stick models. Blue denotes positively
charged residues, red denotes negatively charged residues, and yellow denotes
neutral residues.
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also included 4 single-Cys substitution mutants (i.e., replace-
ments at G119 and E122 (TMD III) and R181 and R189 (TMD
IV)) that based on our earlier studies [10,12] meet this level of
inactivation [10,12]. As is clearly evident from this figure,
looking down into the transport pathway from the cytosolic side
of the bilayer, with the exception of the E122C mutant, the side-
chains of all highly disruptive mutants project into the transport
pathway. Thus as one would expect the precise chemical
architecture of this path is extremely important for function.
4. Discussion
The present investigations sought to address two questions.
First, we sought to understand the molecular basis for our earlier
observation that even though substitution of a Cys at position
120 places it on the water-accessible surface of TMD III, and
that such a Cys is moderately accessible to modification by
MTSES [12], nonetheless citrate was unable to protect against
this modification [13]. This lack of citrate protection strongly
suggested that in the wild-type transporter Leu120 does not
have direct access to the translocation pathway. This conclusion
was somewhat unexpected given that other residues on this face
of the TMD III helix can be protected by citrate and thus do in
fact directly access the transport path. This observation, in
combination with the detailed 3-dimensional CTP homology
model that we recently developed [14], which derived from the
excellent work of Pebay-Peyroula et al. [16] wherein they
determined the crystal structure of the mitochondrial ADP/ATP
carrier, led to the hypothesis that the molecular explanation for
the unexpected inability of citrate to protect against MTSES-
mediated inhibition of the Leu120Cys CTP variant arises fromthe packing arrangement of TMDs III and IV in the CTP
structure [13]. Thus, our model suggests that TMD III packs
against TMD IV at a 30° angle and that this packing
arrangement places the Leu120 side-chain behind the side-
chain of Gln182. This potential explanation led to the testable
hypotheses that: (i) a Cys substituted for Gln182 should be
highly accessible to MTSES in a citrate protectable manner
[13]; and (ii) truncation of the Gln182 side-chain to Ala, should
then render the Leu120Cys mutation accessible to MTSES in a
citrate-protectable manner. The data presented in Fig. 1 fully
support these hypotheses. Thus, substrate protection against
MTSES-mediated inhibition of the CTP function is not
observed with the L120C mutant, but is readily evident with
the Q182C single and the L120C/Q182A double mutants. It is
intriguing that the EC50 value obtained with the double mutant
(0.90 mM) is reasonably close to the Km observed with this
mutant (i.e., 0.30 mM) thereby suggesting the possibility that in
this CTP variant the cysteine at position 120 may play some role
in substrate binding. However, clearly the lack of substrate
protection with the L120C single mutant, suggests that this is
not the case in the presence of the Q182 side-chain which serves
to sterically limit the access of citrate from the translocation
path to the Leu120 side-chain. Fig. 2 depicts the above
explanation of the substrate protection data in the context of our
CTP homology model. Accordingly, a view down into the
transport path from the cytosolic surface shows the steric
blockage by the Gln-182 side-chain of the Leu120 side-chain in
the Cys-less transporter (Panel A), and of the Cys side-chain in
the L120C single mutant (Panel B). Furthermore, the side-chain
of either a Gln or a Cys at position 182 (i.e., Panels A–C)
resides in close contact with the transport path and sterically
blocks access of citrate to the side-chain at position 120.
However, truncation of the Gln side-chain to an Ala at position
182 (Panel D), removes the steric block and now a Cys at
position 120 is fully accessible to citrate from the transport path.
Also, note that a comparison of Panels B versus D in Fig. 2
shows the cysteine side-chain at position 120 existing in
different conformations, which reflects the increased conforma-
tional flexibility that arises from truncation of the Gln182 side-
chain to an alanine. In summary, we believe these experimental
results and interpretations provide important new information
regarding both the packing of α-helical TMDs III and IV in this
critical region and the make-up of this portion of the transport
pathway. Furthermore, our data provide additional evidence in
support of the accuracy and the usefulness of our CTP
homology model for experimental design.
The second issue we sought to address, was the identification
of additional residues that are essential for CTP function. To this
end, we constructed 24 single-Cys mutants, and following
overexpression, solubilization, and reconstitution in liposomal
vesicles, measured their specific citrate transport activities (Fig.
3). It should be noted that these CTP variants were selected based
on our modeling studies which pointed to their potential
involvement in substrate binding and/or translocation. These
mutagenesis investigations resulted in the identification of 10
residues within the CTP that upon mutation to Cys cause a loss of
≥98% of CTP specific activity. Based on this criteria we consider
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E34, K37, K83, R87, Y148, D236, K239, T240, R276, and R279.
Data from our previous investigations indicate that G119, E122,
R181, and R189 are also included in this category [10,12]. As
depicted in Fig. 4, inspection of the location of each of these
essential residues in the context of our CTP homology modeled
structure, indicates that with the single exception of E122, each of
these residues project their side-chains into the substrate
translocation pathway. Furthermore, our current studies in
combination with our earlier investigations [11,12] indicate that
single-Cys replacements for S123, E131, K134, D140, Q182, and
Q243 result in 96–98% inactivation of CTP function and thus
these residues, while perhaps not essential, are nonetheless clearly
important for CTP function. Inspection of the location of the side-
chains of this latter group of amino acids, indicates that they too
project into the transport path (data not shown; Note: the side-
chain of D140 is present in a loop and can likely adopt multiple
conformations some of which project into the pathway and others
of which do not). We hypothesize that subsets of the mutation-
intolerant residues are involved in different functions. For
example, one subset will likely be involved in salt bridge
formation in order to maintain CTP native conformation and/or
facilitate conformational changes associated with transport. A
second set will likely comprise the lining of the transport path, and
a third subset will directly participate in substrate binding. With
respect to E122, an essential residue whose side-chain projects
away from the transport path, we have proposed that it may be
involved in the coordination of the presumed conformational
changes that must occur in each monomer of the homodimer
during a transport cycle [14]. Furthermore, the flexible G119 can
likely be accessed from both the transport pathway as well as the
dimer interface and we have hypothesized may represent an
important component of the latter (G119) [12]. Experimental
efforts are currently underway in our laboratory which seek to
define the precise role of each of the essential residues in the
structure-based mechanism of the CTP.
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